

Supplementary Table 16: Goodness of fit statistics for IPW comparison of UC patients from start 1L to censoring

Characteristic	Difference (ADA – IFX) ¹	95% CI ¹	Difference (GOL – IFX) ¹	95% CI ¹	Difference (TOF – IFX) ¹	95% CI ¹	Difference (UST – IFX) ¹	95% CI ¹	Difference (VDZ – IFX) ¹	95% CI ¹
Patient Sex	0.01	-0.13, 0.14	0.11	-0.02, 0.25	0.01	-0.13, 0.15	0.17	0.04, 0.31	0.00	-0.13, 0.14
Patient Age	0.00	-0.13, 0.14	0.09	-0.05, 0.22	0.16	0.03, 0.30	0.18	0.05, 0.31	0.00	-0.13, 0.14
CCI	0.00	-0.13, 0.14	0.04	-0.10, 0.17	0.29	0.16, 0.43	-0.01	-0.15, 0.12	0.01	-0.13, 0.14
Number of cortico- steroid prescriptions	0.00	-0.13, 0.14	0.08	-0.06, 0.21	0.01	-0.13, 0.14	0.11	-0.02, 0.25	0.01	-0.12, 0.15
Number of hospitali- zations	-0.01	-0.15, 0.12	-0.05	-0.19, 0.08	-0.06	-0.20, 0.07	-0.01	-0.14, 0.13	0.00	-0.13, 0.14
Number of comor- bidities	0.00	-0.13, 0.14	-0.01	-0.14, 0.13	0.03	-0.11, 0.17	-0.16	-0.29, -0.03	0.00	-0.14, 0.13
Number of injuries in follow-up	0.00	-0.14, 0.13	0.16	0.02, 0.29	-0.06	-0.20, 0.07	0.17	0.04, 0.31	0.05	-0.09, 0.18

ADA= Adalimumab CCI = Charlson Comorbidity Index CI = Confidence Interval IFX = Infliximab IPW = inverse probability weighting GOL= Golimumab TOF= Tofacitinib UC = Ulcerative Colitis UST= Ustekinumab VDZ= Vedolizumab

¹Standardized Mean Difference